Terloc

Quick links to important sections

Terloc

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terloc

Quick Facts

Property Description
Active Ingredient Amlodipine Besilate
Form Oral tablets, oral solution, suspension
Pharmacological Class Calcium Channel Blocker (CCB)
General Purpose Reduction of circulatory resistance
Origin Synthetic, Small Molecule

Terloc: A Definitive Identity and Pharmacological Class

Terloc is a medication identified by its active ingredient, Amlodipine Besilate, which is a synthetic compound classified as a Calcium Channel Blocker (CCB), specifically of the dihydropyridine subclass. This pharmacological classification establishes the drug’s function as an agent that modifies the movement of calcium ions within cardiovascular tissues. The medication is prescribed for oral administration, typically as tablets, but liquid preparations, such as an oral solution or suspension, are also available to facilitate patient needs, including administration to certain pediatric patient groups. This accessibility in varied forms is a key feature differentiating the preparation. The medication is used as a single-agent product (Monotherapy), though the compound Amlodipine is widely integrated into combination therapy formulations.

General Purpose: Easing the Circulatory System’s Workload

The general purpose of Terloc is to reduce resistance within the body's circulatory system, thereby lessening the overall effort required of the heart. The active ingredient functions as a potent Peripheral Arterial Vasodilator, causing the walls of the arteries to relax and widen. This effect is achieved through the compound's ability to inhibit the influx of calcium ions into vascular cells, which is the core mechanism of the medication. By lowering the overall peripheral vascular resistance, the medication reduces the force the heart must overcome to pump blood (reduction in afterload). Amlodipine is clinically recognized for its long-acting properties, allowing for sustained and reliable management of circulatory dynamics over a full day.

Regulatory References

  1. Amlodipine MedlinePlus Drug Information
  2. Amlodipine Mechanism of Action (StatPearls)

What side effects are possible with Terloc?

Possible Side Effects and Safety Information

The officially documented safety profile for Terloc (Amlodipine Besilate) is structured by government regulatory documents, detailing expected adverse reactions and safety constraints.

Adverse Reaction Frequencies and Systems

Adverse reactions are classified by incidence rate. Common reactions (occurring in 1/100 to <1/10 patients) often relate to the medication's vasodilatory effects, including edema (swelling, particularly in the ankles), headache, and flushing. Other common effects include fatigue, nausea, and dizziness. Effects are grouped by the affected physiological system, encompassing Vascular (flushing, hypotension), Nervous System (somnolence, tremor), Gastrointestinal, and Cardiac disorders.

Uncommon and Rare effects are also documented, with Very Rare events (<1/10,000) including severe skin reactions such as Erythema multiforme and Stevens-Johnson syndrome, as well as reports of Myocardial Infarction and Hepatic Failure.

Safety Considerations and Patterns

The incidence of edema is explicitly noted in labeling as dose-related. Certain central nervous system effects, such as somnolence and dizziness, are reported to occur more frequently at the beginning of treatment.

Regulatory documents highlight safety considerations for specific populations. For patients with hepatic impairment, slow dose titration is specified due to decreased clearance. Older adults may also require a lower initial dose. Caution is noted for patients with severe aortic stenosis due to the possibility of symptomatic hypotension and for those with congestive heart failure due to a reported increased risk of pulmonary oedema.

Overdose and Emergency Response

A Terloc (Amlodipine Besilate) overdose can lead to severe and prolonged physiological effects, primarily related to the drug's potent vasodilation. Officially documented clinical manifestations center on the cardiovascular system, including profound hypotension (extremely low blood pressure), bradycardia (slow heartbeat), or tachycardia (rapid heartbeat). Other signs listed in regulatory documents include dizziness, fainting (syncope), drowsiness, and metabolic changes such as hyperglycemia (increased blood sugar) or **lactic acidosis).

Overdose may escalate to life-threatening outcomes, including vasodilatory shock and cardiovascular collapse. Severe complications officially documented include non-cardiogenic pulmonary edema and seizure.

When overdose is suspected, immediate emergency medical attention is required. Urgent contact with emergency services is mandated if the individual exhibits severe symptoms such as collapse, unconsciousness, seizures, or trouble breathing.

Management is strictly symptomatic and supportive, as no specific antidote is known for Amlodipine Besilate. Treatment procedures described in official documents include the administration of intravenous fluids and vasopressors to manage hypotension, and specific interventions like intravenous calcium infusion. Due to the drug’s long duration of action, extended hospital monitoring and observation are required.

Therapeutic Uses of Terloc

What Terloc Treats: Main Uses and Benefits

Terloc (Amlodipine Besilate) is commonly used across domains where additional symptomatic support is needed for managing specific chronic cardiovascular conditions, including hypertension (high blood pressure). This medicine is generally relevant for easing symptoms related to systemic imbalance and contributes to the management of cardiovascular risk factors associated with elevated pressure. This supports general well-being during symptomatic phases. The medication is also applied in clinical settings for the management of Chronic Stable Angina and Vasospastic Angina. It is relevant for easing symptoms linked to organ-specific functional stress, such as chest pain manifestations, and may assist in easing the frequency and intensity of these manifestations. It helps maintain a sense of stability, and is commonly used as part of long-term maintenance therapy. For patients with documented Coronary Artery Disease, Terloc is generally used across conditions characterized by periods of heightened symptoms. Applied in scenarios where additional management of discomfort is required, it assists with easing the overall symptom burden and may be part of a plan to help manage situations that could require hospitalization due to angina.


Quick Fact: Therapeutic Support

Terloc is relevant for managing symptom clusters linked to elevated physiological activity and organ-specific functional stress, helping to address the recurrence of chest pain episodes and supporting improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Terloc?

The official eligibility profile for Terloc (Amlodipine Besilate) is determined by regulatory-defined contraindications and population-specific restrictions, rather than therapeutic context.

Eligibility Scope

Classification Population/Condition
Contraindicated Known hypersensitivity to amlodipine or dihydropyridine derivatives.
Patients with severe hypotension or cardiogenic shock.
Obstruction of the left ventricular outflow tract (e.g., high-grade aortic stenosis).
Not Recommended Children under 6 years of age (safety and effectiveness not established).
Breastfeeding patients (excreted in human milk; discontinuation advised).
Restricted/Caution Hepatic Impairment: Requires caution; lower initial dosing and slow titration are necessary in severe cases.
Heart Failure: Use with caution, as an increased incidence of pulmonary edema has been reported in certain non-ischemic patients.
Allowed Adults for all approved indications.
Pediatric patients aged 6 to 17 years for hypertension only.

Eligibility Classifications (High-Level)

  • Age-Related Eligibility: Approved for adults and children 6 to 17 years (hypertension only); not established for children under 6 years.
  • Physiological Restrictions: Caution is mandatory in patients with impaired liver function or pre-existing congestive heart failure.
  • Pregnancy Status: Use is generally reserved for cases where the potential benefit justifies the potential risk, as safety in human pregnancy is not established.

Connection to the overall eligibility profile:

Regulatory documents define patient eligibility by imposing strict non-eligibility for individuals with acute circulatory instability or known allergy. Use is permitted for adults and certain pediatric groups, but conditional on physiological status, specifically requiring caution and dose adjustment for patients with impaired hepatic function or advanced age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Terloc (Amlodipine Besilate) is primarily defined by its effects on drug metabolism and additive pharmacodynamic effects, as documented in official government regulatory information.

Documented Pharmacokinetic Interactions

Interaction Type Interacting Substances/Category
Increased Terloc Exposure Strong and moderate CYP3A inhibitors (e.g., Clarithromycin, Itraconazole, Diltiazem, Verapamil). Co-administration results in increased systemic exposure to Terloc.
Decreased Terloc Exposure CYP3A inducers (e.g., Rifampicin, St John's Wort). Co-administration may cause plasma concentrations to vary and requires monitoring.
Increased Co-Drug Exposure Simvastatin (co-administration significantly increases Simvastatin exposure); Immunosuppressants (e.g., Tacrolimus, Cyclosporine); mTOR Inhibitors (e.g., Sirolimus, Everolimus).

Official Interaction Restrictions and Constraints

  • Dose Limitation: The regulatory label requires that the co-administered dose of Simvastatin must be limited to 20 mg daily due to the risk of increased exposure of the co-drug.
  • Avoidance/Non-Recommendation: Co-administration with Dantrolene (infusion) should be avoided. Consumption of Grapefruit or Grapefruit juice is not recommended as it may increase Terloc bioavailability.
  • Pharmacodynamic Additive Effect: Combining Terloc with other antihypertensive agents or PDE5 inhibitors (e.g., Sildenafil) may lead to an additive blood pressure lowering effect.
  • Population Note: Decreased clearance and increased systemic exposure of Terloc is documented in patients with Severe Hepatic Impairment.

Mechanism of Action

How Terloc Works: Mechanism of Action

Terloc (Amlodipine Besilate) is a compound whose action is defined by the inhibition of voltage-dependent L-type Calcium Channels (L-CCs), primarily located within the cell membranes of vascular smooth muscle cells in the peripheral arteries. This mechanism involves the physical blockade of the channel pore, which arrests the necessary influx of extracellular calcium ions (Ca^2+) required for cellular contraction. The inhibitory action exhibits high vascular-to-cardiac selectivity, favoring the peripheral circulatory system over the myocardial conduction system.

This molecular event disrupts the excitation-contraction coupling sequence in the arterial wall, leading to sustained relaxation (vasodilation) of the peripheral arteries. The resulting reduction in arterial tension causes a marked decrease in the mechanical resistance against which the heart must pump blood. This physiological change, defined as a reduction in Total Peripheral Resistance (TPR) and subsequent afterload, is the core systemic consequence of the mechanism. The drug’s slow binding kinetics cause this physiological adjustment to be gradual and sustained.

Dosage and Administration Information

How to Use Terloc — Official Administration Guidelines

Terloc (terlipressin) must be administered by a healthcare professional in the hospital setting as an intravenous (IV) injection through either a central or peripheral line.

Preparation and Administration

Each single-dose vial must be reconstituted with 5 mL of 0.9% Sodium Chloride Injection to prepare the solution. The reconstituted solution must be visually inspected for particulate matter and discoloration before use. The final solution is administered by slow IV bolus injection over two minutes, and the infusion line must be flushed after administration.

Official Dosing Schedule

The treatment follows a specific, monitored schedule in adult patients:

Treatment Phase Dosing and Frequency Monitoring Requirement
Days 1–3 (Initial) 0.85 mg (1 vial) every 6 hours Record baseline Serum Creatinine (SCr) and baseline oxygen saturation (SpO2) before the first dose
Day 4 (Adjustment) Dose is adjusted based on SCr change from baseline Assess SCr on Day 4 to determine if the dose continues at 0.85 mg or increases to 1.7 mg (2 vials) every 6 hours

Treatment must continue until the patient achieves two consecutive SCr values of ≤ 1.5 mg/dL (at least two hours apart) for a period of 24 hours, or for a maximum duration of 14 days. If the patient's SCr is at or above the baseline value on Day 4, the drug must be discontinued. Throughout the course of treatment, the patient's oxygen saturation must be monitored using continuous pulse oximetry.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Terloc (Amlodipine Besilate)

This section provides a descriptive overview of the research studies conducted for Terloc, detailing the contexts and populations in which Terloc was studied, the types of measurements reported, and the aspects that remain uncertain.


Evidence for Use in Managing Hypertension (High Blood Pressure)

Terloc was widely studied for the management of high blood pressure (hypertension) in large-scale, multi-center Randomized Controlled Trials (RCTs) and systematic reviews exploring chronic conditions characterized by functional limitations. Studies monitored changes in blood pressure and were evaluated for outcomes related to systemic or functional imbalance, such as changes in systolic and diastolic blood pressure over the defined study intervals. Researchers also tracked the occurrence of pre-defined cardiovascular outcomes over follow-up durations lasting several years.

Findings describe patterns observed in the studies related to measured changes in blood pressure readings in the observed groups. Certain comparative studies examined patterns related to pre-defined cardiovascular outcomes in cohorts using regimens including Terloc. Data for certain groups remain insufficient regarding long-term pre-defined cardiovascular outcomes, particularly for specific populations that were excluded from the largest trials.

Evidence for Use in Chronic Stable Angina and Coronary Artery Disease

Evidence was evaluated in placebo-controlled RCTs and comparative studies that focused on populations with chronic stable angina. Research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, such as the time until symptoms arose during exercise testing.

Findings describe patterns observed in the studies related to the patient-reported frequency of angina attacks in the observed groups. Research highlights measurements collected during the study period, including data on the ability of participants to tolerate exercise before symptoms became more noticeable. These reported outcomes were focused on functional capacity and measurements related to short- to intermediate-term changes in symptoms.

Evidence for Vasospastic Angina

Research describes patterns related to the frequency of episodic or acute changes reported in the study groups over defined time intervals. This evidence provides context but is based on smaller sample sizes and limited follow-up durations compared to the hypertension research.

Research Gaps and Areas of Uncertainty

There is limited information for long-term outcomes in the pediatric population to compare long-term cardiovascular outcomes with those seen in adults. Data for certain groups remain insufficient, particularly for individuals with specific, severe heart conditions. In these cases, certainty remains low, and the results apply only to the populations studied in the specific trials. Comparative evidence is also lacking for certain specific combinations or narrowly defined patient subgroups.

Key Studies & References

  1. Amlodipine - FDA Verification Portal (Indications, safety in poor cardiac reserve, use in vasospastic angina)
  2. Amlodipine Besylate Trade Name (Norvask CDS) - Pediatric Patients (ages 6-17 years) efficacy study
  3. Impact of amlodipine on clinical outcomes for heart failure in patients with dilated cardiomyopathy: a Korean nationwide cohort study (Discusses PRAISE 1 and 2 inconsistencies)

Frequently Asked Questions (FAQ)

Common questions about Terloc (FAQ)

Q: Are there common foods or drinks that should be avoided while taking Terloc?

A: Official documents indicate that the consumption of Grapefruit or Grapefruit juice is not recommended due to the potential for interaction. Additionally, alcohol (ethanol) may have an additive effect in lowering your blood pressure when taken with Terloc, which could increase the risk of symptoms like dizziness and fainting.

Q: What kind of warnings or precautions are listed for Terloc?

A: Official safety documents list several precautions. These include the possibility of symptomatic hypotension (low blood pressure) and the potential for worsening chest pain (angina) when starting treatment. Caution is also noted in regulatory guidelines for patients who have pre-existing liver impairment.

Q: How quickly is Terloc expected to start working?

A: Following a single dose, a decrease in blood pressure is typically observed over a period of 4 to 8 hours. For the medication to reach stable blood concentrations, official regulatory documentation describes this as usually occurring after 7 to 10 days of consistent daily use.

Q: Can Terloc be taken by people who are also managing blood pressure issues?

A: Terloc itself is a blood pressure-lowering medicine, and its active ingredient is often used as part of combination therapy. Regulatory documentation states that it is frequently included in treatment regimens alongside other types of antihypertensive agents to manage blood pressure.

Q: What is the difference between Terloc and other similar medicines I've heard about?

A: Terloc's active ingredient is specifically classified as a dihydropyridine Calcium Channel Blocker (CCB). This is a specific category of medicine that works primarily by relaxing and widening the blood vessels, rather than directly affecting the heart muscle like other types of CCBs.

Q: Is it true that Terloc can cause stomach upset?

A: Official safety data reports specific adverse effects, such as nausea and abdominal pain, that are considered common. These side effects are documented as occurring in 1% to 10% of patients.

Q: How long does the effect of one dose of Terloc typically last?

A: The medication is known for its long-acting properties due to how slowly the body processes it. The time it takes for half of the drug to be cleared, known as the terminal elimination half-life, typically ranges from 40 to 50 hours. This long half-life supports the sustained management of circulatory dynamics.

Q: Is Terloc generally considered safe for elderly patients?

A: Regulatory documentation notes that older adults may process the drug more slowly, which can lead to higher levels in the body and an increased risk of side effects. For this reason, official product labeling indicates that dose consideration, such as a lower initial dose, may be necessary for this population.

Q: Are there any major studies or clinical trials that support the use of Terloc?

A: The active ingredient in Terloc was evaluated for safety and efficacy in clinical trials involving more than 11,000 patients across U.S. and international studies, according to official documents.

Q: Is it normal to feel a bit drowsy after starting Terloc?

A: Official documents list somnolence (drowsiness) and dizziness as common side effects. Regulatory safety information notes that these effects are reported to occur more frequently at the beginning of treatment.

Q: Is Terloc safe to use for a long period of time?

A: Terloc is indicated for the management of chronic conditions, such as high blood pressure. However, regulatory texts describe the drug's use in terms of efficacy and risk, and do not use the term 'safe' to classify long-term use.

Q: Is Terloc a controlled substance or habit-forming?

A: Regulatory drug facts confirm that Terloc's active ingredient is not classified as a controlled medication. Based on its pharmacological classification, it is not considered habit-forming.

Q: Is Terloc available over the counter in any country?

A: According to official regulatory drug facts, the active ingredient in Terloc is listed as being prescription-only.

Q: Is there a generic version of Terloc available yet?

A: An FDA-approved generic version of the active ingredient, Amlodipine Besilate, is currently available on the market.

Q: Does alcohol consumption present a significant interaction risk with Terloc?

A: Regulatory warnings indicate that alcohol (ethanol) may have additive effects with Terloc in lowering blood pressure. This additive lowering effect can potentially lead to symptoms such as dizziness and fainting.

Q: Are there specific symptoms that require immediate medical attention while on Terloc?

A: Official regulatory warnings describe circumstances where emergency medical attention should be sought, such as sudden or worsening severe chest pain, signs of a severe allergic reaction (such as swelling of the face, tongue, or throat), or symptoms consistent with a heart attack.

Q: What is the approved age range for Terloc use?

A: The medication is approved for use in adults for all its established indications. It is also approved for pediatric patients aged 6 to 17 years for the treatment of high blood pressure (hypertension) only.

Q: What kind of warnings are included about taking Terloc with herbal supplements?

A: Official warnings specifically indicate that the herbal supplement St John's Wort is thought to affect the way Terloc works by potentially decreasing its concentration in the body.

Q: If I stop taking Terloc, are there any known rebound effects?

A: Studies and official information indicate that when the medication is discontinued, blood pressure levels gradually return to pre-treatment levels. There is no evidence of a rebound effect, which is an unwanted sudden or rapid increase in blood pressure.

Q: Does Terloc cause weight changes?

A: Changes in weight, including both weight gain and weight decrease, have been reported in official documents. Weight gain may be an observation related to the common side effect of edema (swelling or fluid retention).

Q: Is Terloc often prescribed alongside any other medications?

A: While the drug is widely used as a single agent (monotherapy), its active ingredient is integrated into many combination therapy formulations, which are used in conjunction with other medications (e.g., statins, other blood pressure treatments).

Q: Does taking Terloc affect my ability to drive or operate machinery?

A: Official product information states that the medication may have a minor or moderate influence on the ability to drive or operate machinery. Regulatory labeling indicates that caution should be exercised, particularly at the start of treatment, if side effects such as dizziness or fatigue occur.

Q: Does Terloc have an official black box warning?

A: The specific term 'black box warning' is not used on the regulatory label for the active ingredient when prescribed as a single agent (monotherapy).

Q: How long after taking Terloc is it generally eliminated from the body?

A: Terloc is slowly cleared from the body. Regulatory pharmacokinetics data state that the terminal elimination half-life, which represents the time required for the concentration to halve, typically ranges from 40 to 50 hours.

Q: Is Terloc known to cause problems with eyesight or vision?

A: Official safety documents list visual side effects, including abnormal vision and diplopia (double vision). However, these specific effects are classified as uncommon or rare events in the adverse reaction profile.

How should Terloc be stored and disposed of?

How to Store and Dispose of Terloc

Terloc (Amlodipine Besilate) tablets require specific storage conditions to maintain product stability, as documented in regulatory labeling.


Official Storage Requirements

Item Requirement
Temperature Store at controlled room temperature: 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the product in its original container and protected from excessive moisture.
Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets should be managed through a drug take-back program if one is available in the community. If not, the tablets can be prepared for household trash by mixing them with an undesirable substance (e.g., used coffee grounds) in a sealed container. The medicine must not be thrown into wastewater (flushed down the toilet or poured down a sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terloc found in:

A-Z Index: